[Hematopoietic stem cells mobilization: state of the art in 2011 and perspectives].
High-dose chemotherapy with stem cells support has largely improved in terms of hematopoietic stem and progenitor cells harvest procedures as well as in those, which target or manipulate the cellular composition of autologous graft. Optimal preparative regimens and supportive care had lead to better use of autologous transplantation procedure. For other patients assigned to hematopoietic transplantation, availability of allogeneic donors appears to be an interesting alternative source of hematopoietic stem cells. Since three decades, hematopoietic growth factors development has allowed mobilization optimization and collection of peripheral hematopoietic stem cells leading to reduced days of hospitalization and less blood products requirements, being more cost-effective for patients in autologous transplantation settings and for stem cell collection facilities in allogeneic ones. New perspectives include, besides ex vivo manipulation of graft, development of mobilizing drugs in order to perform transplantation even in poor mobilizers patients. An important goal is achieved with the description of genetic polymorphisms related to optimal mobilization of stem cells. New approach using more promising and selective agents called chemokines, such as plerixafor the main leader among these agents are now available and appear complementary for alternative approach using cytokines alone (G-CSF, GM-CSF, SCF). The aim of this review is to assess the evolution of theses biotechnologies and their role in different steps of autologous transplantation and allogeneic stem cells collection.
Établissement français du sang Aquitaine-Limousin, place Amélie-Raba-Léon, 33035 Bordeaux cedex, France. fontanet.bijou@efs.sante.fr
F
F
Bijou
Z
Z
Ivanovic
J M
JM
Boiron
F
F
Nicolini
D001596:Benzylamines; D001781:Blood Component Removal; D015815:Cell Adhesion Molecules / Q000037:antagonists & inhibitors; D018925:Chemokines / Q000494:pharmacology; D000080027:Cyclams; D000069585:Filgrastim; D016179:Granulocyte Colony-Stimulating Factor / Q000494:pharmacology; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000494:pharmacology; D013006:Growth Hormone / Q000494:pharmacology; D019650:Hematopoietic Stem Cell Mobilization / Q000379:methods / Q000639:trends; D018380:Hematopoietic Stem Cell Transplantation; D006571:Heterocyclic Compounds / Q000494:pharmacology; D006801:Humans; D010281:Parathyroid Hormone / Q000494:pharmacology; D011092:Polyethylene Glycols; D019707:Receptors, Chemokine / Q000037:antagonists & inhibitors; D011994:Recombinant Proteins / Q000494:pharmacology; D019089:Stem Cell Factor / Q000494:pharmacology; D014182:Transplantation, Autologous
D001596:Benzylamines; D015815:Cell Adhesion Molecules; D018925:Chemokines; D000080027:Cyclams; D006571:Heterocyclic Compounds; D010281:Parathyroid Hormone; D019707:Receptors, Chemokine; D011994:Recombinant Proteins; D019089:Stem Cell Factor; D016179:Granulocyte Colony-Stimulating Factor; C455861:pegfilgrastim; D011092:Polyethylene Glycols; D016178:Granulocyte-Macrophage Colony-Stimulating Factor; D013006:Growth Hormone; D000069585:Filgrastim; C088327:plerixafor